Dossier assessment

Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more prior systemic therapies

Result of dossier assessment:

Patients who are eligible for CAR-T cell therapy or stem cell therapy: added benefit not proven
Patients who are not eligible for CAR-T cell therapy and stem cell therapy: added benefit not proven

17.04.2025 A G-BA decision was published.
G-BA documents on this decision

Project no.: A24-108
Commission: Commission awarded on 01.11.2024 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A24-108_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.